secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053952
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus reports Q1 net loss $63.5M; announces $100M royalty financing with Ligand
--------------------------------------------------------------------------------

- Net loss narrowed to $63.5M ($3.04/shr) from $70.9M ($4.31/shr) a year ago; revenue $28M.
- Cash and equivalents $52.9M at March 31, 2024, vs $76.1M at Dec 31, 2023; Q1 cash burn $38.2M.
- Signed $100M royalty financing with Ligand ($75M initial + $25M option) to fund BOT/BAL launch readiness.
- BOT/BAL Phase 1b in r/r MSS CRC NLM (n=77): 23% ORR, median OS 21.2 months, 12-month OS 71%.
- Regained Nasdaq compliance after 20:1 reverse stock split in Q1 2024; plan BLA submission for BOT/BAL in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024053952/0000950170-24-053952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017024053952/agen-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer